Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts ...

(Reuters) -Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign ...

Abbott has scored yet another Emergency Use Authorization for rapid coronavirus testing – this one, named BinaxNOW COVID-19 Ag Card, come in the form of a card and can provide results in 15 minutes.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Shares of Abbott Laboratories fell 3% on Wednesday after the diversified health-care company delivered another less-than-stellar quarter. Revenue in the third quarter ended Sept. 30 rose 6.9% to ...

Breaking down segments: Medical Devices led with 12% growth (Diabetes Care +19.5%, Heart Failure +14%, Structural Heart +12%). Nutrition +3.5% (Adult +6.5% on Ensure/Glucerna). EPD +8% (Key 15 markets ...